FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285744084> ?p ?o ?g. }

• W4285744084 endingPage "10" @default.
• W4285744084 startingPage "1" @default.
• W4285744084 abstract "Objective. To compare the merits and demerits of PEG-IFNα-2a and PEG-IFNα-2b for the treatment of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB). Methods. Clinical files from eighty-four CHB patients admitted to the Second Hospital of Shanxi Medical University between January 2018 and January 2019 were retrospectively analyzed and assigned to two groups: group 2a treated with PEG-IFNα-2a and group 2b treated with PEG-IFNα-2b. The clinical efficacy was compared between the above two arms, and the liver function (ALT, AST, HA, LN, and IV-C), HBV-DNA, HBsAg, HBeAg, and inflammatory factors (IFs, IL-1β, IL-6, IL-8, and TNF-α) were tested at 12 weeks (T1), 24 weeks (T2), and 48 weeks (T3). The alterations of hemodynamics (SBP, DBP, MAP, and CVP), cardiac function (LVEF and BNP), and the incidence of adverse reactions (ARs) during treatment were recorded. Finally, the patients were followed up for 2 years to investigate the quality of life (QOL) as well as the positive seroconversion rate of HBsAg and HBeAg. Results. The overall response rate was similar in the two arms ( <math xmlns=http://www.w3.org/1998/Math/MathML id=M1> <mi>P</mi> <mo>></mo> <mn>0.05</mn> </math> ). After treatment, the liver function, HBV-DNA, HBsAg, HBeAg, IFs, hemodynamics, and cardiac function were enormously improved ( <math xmlns=http://www.w3.org/1998/Math/MathML id=M2> <mi>P</mi> <mo><</mo> <mn>0.05</mn> </math> ), with faster improvement in group 2b compared with group 2a ( <math xmlns=http://www.w3.org/1998/Math/MathML id=M3> <mi>P</mi> <mo><</mo> <mn>0.05</mn> </math> ). The investigation of ARs identified notably lower incidence rates of alopecia, thrombocytopenia, and granulocytopenia in group 2a as compared to group 2b ( <math xmlns=http://www.w3.org/1998/Math/MathML id=M4> <mi>P</mi> <mo><</mo> <mn>0.05</mn> </math> ). The prognostic follow-up results revealed no distinct difference in the QOL score and the positive seroconversion rate of HBsAg and HBeAg ( <math xmlns=http://www.w3.org/1998/Math/MathML id=M5> <mi>P</mi> <mo>></mo> <mn>0.05</mn> </math> ); however, the quantitative results of HBV-DNA, HBsAg, and HBeAg in group 2b were lower than those in group 2a ( <math xmlns=http://www.w3.org/1998/Math/MathML id=M6> <mi>P</mi> <mo><</mo> <mn>0.05</mn> </math> ). Conclusions. Both PEG-IFNα-2a and PEG-IFNα-2b have excellent and stable therapeutic effects on HBeAg-positive CHB, among which PEG-IFNα-2b renders a faster treatment process but higher side effects, which can provide valuable references when choosing a treatment plan for CHB." @default.
• W4285744084 created "2022-07-18" @default.
• W4285744084 creator A5020355643 @default.
• W4285744084 creator A5037697156 @default.
• W4285744084 creator A5055282487 @default.
• W4285744084 creator A5065120882 @default.
• W4285744084 creator A5073021091 @default.
• W4285744084 creator A5081020048 @default.
• W4285744084 creator A5005308785 @default.
• W4285744084 date "2022-06-11" @default.
• W4285744084 modified "2023-10-01" @default.
• W4285744084 title "Clinical Efficacy of PEG-IFNα-2a and PEG-IFNα-2b in the Treatment of Hepatitis B e Antigen-Positive Hepatitis B and Their Value in Improving Inflammatory Factors and Hemodynamics in Patients: A Comparative Study" @default.
• W4285744084 cites W1481774199 @default.
• W4285744084 cites W1975597436 @default.
• W4285744084 cites W1997544244 @default.
• W4285744084 cites W2023718741 @default.
• W4285744084 cites W2061135716 @default.
• W4285744084 cites W2074676714 @default.
• W4285744084 cites W2101622976 @default.
• W4285744084 cites W2147283902 @default.
• W4285744084 cites W2147403937 @default.
• W4285744084 cites W2173698250 @default.
• W4285744084 cites W2173855355 @default.
• W4285744084 cites W2179532552 @default.
• W4285744084 cites W2406978749 @default.
• W4285744084 cites W2419640663 @default.
• W4285744084 cites W2594140396 @default.
• W4285744084 cites W2605785536 @default.
• W4285744084 cites W2766928735 @default.
• W4285744084 cites W2888081930 @default.
• W4285744084 cites W2896368833 @default.
• W4285744084 cites W2899672256 @default.
• W4285744084 cites W2932900696 @default.
• W4285744084 cites W2938700217 @default.
• W4285744084 cites W2990371616 @default.
• W4285744084 cites W2999691010 @default.
• W4285744084 cites W3005660153 @default.
• W4285744084 cites W3022296307 @default.
• W4285744084 cites W3025140871 @default.
• W4285744084 cites W3033418757 @default.
• W4285744084 cites W3037575743 @default.
• W4285744084 cites W3041728167 @default.
• W4285744084 cites W3120808341 @default.
• W4285744084 cites W577533421 @default.
• W4285744084 doi "https://doi.org/10.1155/2022/3185320" @default.
• W4285744084 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35726331" @default.
• W4285744084 hasPublicationYear "2022" @default.
• W4285744084 type Work @default.
• W4285744084 citedByCount "3" @default.
• W4285744084 countsByYear W42857440842023 @default.
• W4285744084 crossrefType "journal-article" @default.
• W4285744084 hasAuthorship W4285744084A5005308785 @default.
• W4285744084 hasAuthorship W4285744084A5020355643 @default.
• W4285744084 hasAuthorship W4285744084A5037697156 @default.
• W4285744084 hasAuthorship W4285744084A5055282487 @default.
• W4285744084 hasAuthorship W4285744084A5065120882 @default.
• W4285744084 hasAuthorship W4285744084A5073021091 @default.
• W4285744084 hasAuthorship W4285744084A5081020048 @default.
• W4285744084 hasBestOaLocation W42857440841 @default.
• W4285744084 hasConcept C126322002 @default.
• W4285744084 hasConcept C178853913 @default.
• W4285744084 hasConcept C203014093 @default.
• W4285744084 hasConcept C2522874641 @default.
• W4285744084 hasConcept C2775940106 @default.
• W4285744084 hasConcept C2776461080 @default.
• W4285744084 hasConcept C2777382497 @default.
• W4285744084 hasConcept C2777410769 @default.
• W4285744084 hasConcept C2777451964 @default.
• W4285744084 hasConcept C2778198053 @default.
• W4285744084 hasConcept C2780040827 @default.
• W4285744084 hasConcept C2780593183 @default.
• W4285744084 hasConcept C2992208098 @default.
• W4285744084 hasConcept C3020491458 @default.
• W4285744084 hasConcept C71924100 @default.
• W4285744084 hasConcept C78085059 @default.
• W4285744084 hasConcept C90924648 @default.
• W4285744084 hasConceptScore W4285744084C126322002 @default.
• W4285744084 hasConceptScore W4285744084C178853913 @default.
• W4285744084 hasConceptScore W4285744084C203014093 @default.
• W4285744084 hasConceptScore W4285744084C2522874641 @default.
• W4285744084 hasConceptScore W4285744084C2775940106 @default.
• W4285744084 hasConceptScore W4285744084C2776461080 @default.
• W4285744084 hasConceptScore W4285744084C2777382497 @default.
• W4285744084 hasConceptScore W4285744084C2777410769 @default.
• W4285744084 hasConceptScore W4285744084C2777451964 @default.
• W4285744084 hasConceptScore W4285744084C2778198053 @default.
• W4285744084 hasConceptScore W4285744084C2780040827 @default.
• W4285744084 hasConceptScore W4285744084C2780593183 @default.
• W4285744084 hasConceptScore W4285744084C2992208098 @default.
• W4285744084 hasConceptScore W4285744084C3020491458 @default.
• W4285744084 hasConceptScore W4285744084C71924100 @default.
• W4285744084 hasConceptScore W4285744084C78085059 @default.
• W4285744084 hasConceptScore W4285744084C90924648 @default.
• W4285744084 hasLocation W42857440841 @default.
• W4285744084 hasLocation W42857440842 @default.
• W4285744084 hasLocation W42857440843 @default.
• W4285744084 hasOpenAccess W4285744084 @default.
• W4285744084 hasPrimaryLocation W42857440841 @default.

• next